Science & Enterprise subscription

Follow us on Twitter

  • National Institutes of Health is supporting development of an extended-release probiotic treatment for necrotizing…
    about 19 hours ago
  • New post on Science and Enterprise: Small Biz Grant Funds Pre-Term Gut Microbe Therapy #Science #Business
    about 19 hours ago
  • A company developing vaccines with synthetic biology is receiving a grant for a vaccine to prevent infections from…
    about 2 days ago
  • New post on Science and Enterprise: Carb-X Funds Drug-Resistant Bacterial Vaccine #Science #Business
    about 2 days ago
  • Engineers in Europe developed an electronic device that connects to and stimulates the optic nerve, producing simpl…
    about 2 days ago

Please share Science & Enterprise

FDA Approves First Treatment for Scorpion Stings

Bark scorpion (Jeb Zirato/University of Arizona)

Bark scorpion (Jeb Zirato/University of Arizona)

The Food and Drug Administration approved Anascorp, the first specific treatment for a sting by Centruroides scorpions, commonly known as the Arizona Bark Scorpion in the United States. The drug was developed by Rare Disease Therapeutics Inc. in Franklin, Tennessee, licensing research by University of Arizona in Tucson and and two research institutes in Mexico.

University of Arizona says more than 15,000 people in the U.S. report scorpion stings each year, but only a few hundred people a year suffer from severe symptoms. Those symptoms include numbness radiating from the sting site, increased heart rate, agitation, restlessness, abnormal eye movements, drooling, and breathing problems.

Most of these cases are in Arizona, as the desert southwest is the main habitat for the only scorpion species in the United States, the bark scorpion, whose sting occasionally causes these physical responses in people.

FDA says the effectiveness of Anascorp was based on results from a randomized, double-blind, placebo-controlled trial of 15 children with neurological signs of scorpion stings. These signs resolved within four hours of treatment in the eight subjects who received Anascorp, but in only one of the seven participants who received the placebo. In total, safety and efficacy data were collected from 1,534 patients in both open-label and blinded studies.

The antivenom must be administered by a physician and usually will be used in hospital emergency rooms. The product is expected to be available commercially in about a month.

The most common side effects were vomiting, fever, rash, nausea, itchiness, headache, runny nose, and muscle pain. Specialists at the Arizona Poison and Drug Information Center plan to report unusual patient responses to Anascorp immediately to Rare Disease Therapeutics.

Read more: FDA Designates Orphan Drug Made From Tarantula Venom

*     *     *

Please share Science & Enterprise ...

Comments are closed.